Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse

References

• Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579–590.
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969–1978.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013;31(10):1293–1301.
   PubMed Web of Science ®Google Scholar
• Ganzel C, Sun Z, Cripe LD, et al. Very poor long‐term survival in past and more recent studies for relapsed AML patients: the ECOG‐ACRIN experience. Am J Hematol. 2018;93:1074–1081.
   PubMed Web of Science ®Google Scholar
• Ofran Y, Rowe JM. Treatment for relapsed acute myeloid leukemia: what is new? Curr Opin Hematol. 2012;19:89–94.
   PubMed Web of Science ®Google Scholar
• Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013;121(7):1077–1082.
   PubMed Web of Science ®Google Scholar
• Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730–3738.
   PubMed Web of Science ®Google Scholar
• Oyekunle AA, Kröger N, Zabelina T, et al. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant. 2006;37:45–50.
   PubMed Web of Science ®Google Scholar
• Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood.2015;126(3):319–327.
   PubMed Web of Science ®Google Scholar
• Liu Yin JA, Wheatley K, Rees JKH, et al. Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial. Br J Haematol. 2001;113:713–726.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Thiede C, Füssel M, et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia. 2006;20:707–714.
   PubMed Web of Science ®Google Scholar
• Stolzel F, Platzbecker U, Mohr B, et al. Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia. Leukemia. 2013;27:2068–2072.
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108:1092–1099.
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Tischer J, et al. Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study. Bone Marrow Transplant. 2012;47:46–53.
   PubMed Web of Science ®Google Scholar
• Middeke JM, Herbst R, Parmentier S, et al. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016;30(2):261–267.
   PubMed Web of Science ®Google Scholar
• Schetelig J, Schaich M, Schäfer-Eckart K, et al. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Leukemia. 2015;29(5):1060–1068.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1989;4(3):247–254.
   PubMedGoogle Scholar
• Schlenk RF, Döhner H. Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2013;1:324–330.
   Web of Science ®Google Scholar
• Schneidawind D, Federmann B, Faul C, Vogel W, Kanz L, Bethge WA. Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. Ann Hematol. 2013;92(10):1389–1395.
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Hentrich M, et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant. 2008;41(8):721–727.
   PubMed Web of Science ®Google Scholar
• Sheth V, Labopin M, Canaani J, et al. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone Marrow Transplant. 2019;54:531–539.
   PubMed Web of Science ®Google Scholar
• Saraceni F, Labopin M, Brecht A, et al. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). J. Hematol. Oncol. 2019;12:44.
   PubMed Web of Science ®Google Scholar
• Aoki J, Seo S, Kanamori H, et al. Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML. Bone Marrow Transplant. 2016;51:604–606.
   PubMed Web of Science ®Google Scholar
• Al Malki MM, Nathwani N, Yang D, et al. Melphalan-based reduced-intensity conditioning is associated with favorable disease control and acceptable toxicities in patients older than 70 with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(9):1828–1835.
   PubMed Web of Science ®Google Scholar
• Steckel NK, Groth C, Mikesch JH, et al. High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2018;180(6):840–853.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Dewald GW, Gandham S, et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 2007;110:409–417.
   PubMed Web of Science ®Google Scholar
• Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–2361.
   PubMed Web of Science ®Google Scholar
• Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25(5):808–813.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Arbolí E, Labopin M, Tischer J, et al. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2020;26(11):2165–2173.
   PubMed Web of Science ®Google Scholar
• Craddock C, Jackson A, Loke J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39(7):768–778.
   PubMed Web of Science ®Google Scholar
• Todisco E, Ciceri F, Boschini C, et al. Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant. 2017;52:955–961.
   PubMed Web of Science ®Google Scholar
• Pfrepper C, Klink A, Behre G, et al. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol. 2016;142:317–324.
   PubMed Web of Science ®Google Scholar
• Schmid C. Labopin M., Schaap N., et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2019;184:782–787.
   PubMed Web of Science ®Google Scholar
• Jedlickova Z, Schmid C, Koenecke C, et al. Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:663–667.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Middeke JM, Sockel Ket al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;12:1668–1679.
   Web of Science ®Google Scholar
• Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-Negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38(36):4249–4259.
   PubMed Web of Science ®Google Scholar
• Bug G, Burchert A, Wagner E-M, et al. Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia. 2017;31:2523–2525.
   PubMed Web of Science ®Google Scholar
• Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ. Blood and marrow transplant clinical trials network. FLT3 Inhibitor maintenance after allogeneic transplantation: is a placebo-controlled, randomized trial ethical? J Clin Oncol. 2019;37(19):1604–1607.
   PubMed Web of Science ®Google Scholar
• Jetani H, Garcia-Cadenas I, Nerreter T, et al. CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018;32:1168–1179.
   PubMed Web of Science ®Google Scholar
• Fan M, Li M., Gao L.et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. J. Hematol Oncol. 2017;10:151.
   PubMed Web of Science ®Google Scholar